Mevalonate Kinase Deficiency News and Research

RSS

EULAR points-to-consider can guide diagnostic evaluation, treatment and monitoring of SAIDs

SAIDs are a group of multi-system disorders caused by dysfunction in the innate immune system. A number of these SAIDs are mediated by a cytokine called interleukin-1 (IL-1), including the cryopyrin-associated periodic syndromes (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), and deficiency of the IL-1 receptor antagonist (DIRA).

1 Nov 2022

Study provides new insights into the underlying physiology of mevalonate kinase deficiency

A new study from the Garvan Institute of Medical Research shows how rises in core body temperature may trigger the inflammatory flares in people with a rare genetic autoinflammatory disease.

3 Oct 2022

New findings pinpoint key feature of rare childhood disease that could help fast-track diagnosis

Australian scientists have shown, for the first time, that a family of untethered proteins builds up in the cells of children with a rare and serious genetic condition, known as mevalonate kinase deficiency (MKD).

10 May 2017

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.

24 Sep 2016